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Background: Early identification of high-risk individuals is key for the prevention of cardiovascular disease (CVD).
The aim of this study was to assess the potential impact of a family history of metabolic syndrome (fhMetS) on the
risk of metabolic disorders (abnormal body mass, lipid profile, glucose metabolism, insulin resistance, and blood
pressure) in healthy young individuals.
Methods: We studied CVD risk factors in 90 healthy volunteers, aged 27–39 years; of these, 78 had fhMetS and 12
were without fhMetS (control group). Fasting serum lipids, glucose, and insulin levels were assayed, and anthropometric
parameters and blood pressure using, an ambulatory blood pressure monitoring system, were measured. Nutritional and
physical activity habits were assessed.
Results: Despite similar nutritional and physical activity habits, abnormal body mass was found in 53.2% of the fhMetS
participants and 46.1% of the control participants (p = 0.54). The occurrence of obesity was 19.4% and 0%, respectively
(p = 0.69). Compared to the control participants, fhMetS was associated with significantly higher total cholesterol (5.46
mmol/L vs. 4.69 mmol/L, p < 0.030), low-density lipoprotein cholesterol ( 3.28 mmol/L vs. 2.90 mmol/L, p < 0.032), and
non-high-density lipoprotein cholesterol ( 3.74 mmol/L vs. 3.25 mmol/L, p < 0.016) levels, in addition to lower fasting
glucose levels ( 4.51 mmol/L vs. 4.81 mmol/L, p < 0.042). A positive correlation between fasting glucose and insulin
levels (r = 0.28; p < 0.015) was detected in the fhMetS participants. Higher mean daytime systolic blood pressure
(121.5 mmHg vs. 113.3 mmHg, p < 0.035), mean daytime diastolic blood pressure ( 79.0 mmHg vs. 74.5 mmHg,
p < 0.045), and mean nighttime diastolic blood pressure ( 64.0 mmHg vs. 59.5 mmHg, p < 0.019) were observed
in the fhMetS group.
Conclusions: More than 50% of the fhMetS participants had excess weight or a lipid disorder, which may indicate an
increased risk of cardiovascular disease and the need for regular ambulatory assessment of serum lipid concentrations
in young people with a family history of MetS.
Keywords: Metabolic syndrome, Family history, Cardiovascular disease, Risk factorsBackground
Atherosclerotic cardiovascular disease (CVD) continues
to be a major cause of premature mortality worldwide and
is considered by the Wold Health Organization (WHO) to
be a major chronic, noncommunicable disease that results
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continue to increase [1]. The prevalence of atherosclerosis,
even in early life, in addition to its dynamic course and
unfavorable long-term prognosis, especially in young
people, requires novel, easy, accessible, and more ag-
gressive action in primary prevention. The WHO esti-
mates that effective preventive strategies targeted at
established, easy to assess, and modifiable risk factors
such as smoking, obesity, dyslipidemia, diabetes, and ar-
terial hypertension have the potential to reduce thel Ltd. This is an Open Access article distributed under the terms of the Creative
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as 80% [2,3]. However, the fundamental issue remains
how to effectively identify groups of patients with in-
creased cardiovascular risk, especially among the young
and healthy. Several studies have shown that individuals
with a family history of CVD are such a group [4]. The
current 2012 European Guidelines on cardiovascular
disease prevention in clinical practice note an increased
cardiovascular risk in individuals with a family history
of premature CVD. At the same time, the Systematic
COronary Risk Evaluation (SCORE) system includes a gen-
eral approach to family history, which tends to lower the
associated cardiovascular risk [5].
Metabolic syndrome (MetS), includes several particu-
larly unfavorable, proatherogenic, and interacting meta-
bolic disturbances (visceral obesity, hyperinsulinemia,
insulin resistance, elevated serum glucose, dyslipidemia,
and arterial hypertension) and is a major cause of ath-
erosclerotic cardiovascular disease and type 2 diabetes
[6]. The presence of 3 or more of the MetS components
increased the risk of cardiovascular disease 3–5 fold [7].
The incidence of MetS is also increasing, and studies in-
dicate that the current incidence is 10- 30% in various
populations worldwide [7-10]. Studies have demonstrated
a strong genetic basis for MetS components; therefore,
young people with a family history of MetS could be
regarded to be at higher cardiovascular risk and included
in early preventive efforts to reduce those risk factors.
However, evidence regarding the best methods to identify
those at higher risk is lacking. We hypothesized that ap-
parently healthy offspring of parents with MetS may dem-
onstrate metabolic alterations that are typical for MetS.
Owing to the increased prevalence of MetS in the general
population, it is likely that clinicians will encounter in-
creasing numbers of young patients with a family history
of MetS. To the best of our knowledge, this popula-
tion has not yet been analyzed. Therefore, the aim of
this study was to characterize young, clinically healthy
adults with a family history of MetS and assess the typical
features of MetS (abnormal body mass, lipid and carbohy-
drate metabolic disorders, insulin resistance, and arterial
hypertension) in this same group.
Material and methods
Subjects and study design
The study sample consisted of 90 healthy subjects
(50 women, 40 men) aged 27 – 39 years with no clinical
signs of atherosclerosis. To identify the subjects for the
study group, we asked approximately 2000 patients from
our Diabetic and Cardiac Outpatient clinics to refer their
healthy adult children to our study. From the group of
211 patients who agreed to refer their children, we se-
lected 160 patients with definitive MetS, and we screened
their 150 children. Of these, 78 healthy adults offspringof the parents with confirmed MetS were enrolled in the
study and considered the family history of metabolic syn-
drome (fhMetS) group. The control group included 12
persons with no family history of MetS who were se-
lected from a group of 20 subjects who matched the
demographic characteristics of the study group with a
special focus on nutritional habits and physical activity.
The exclusion criteria included: symptomatic atheroscler-
osis, i.e. coronary artery disease, arterial occlusive disease,
or arterial hypertension; history of stroke or TIA; heart
defect, heart failure, diabetes, thyroid disease, acute or
chronic inflammatory process, connective tissue disorder,
allergic disease, kidney disease (estimated glomerular fil-
tration rate < 60 ml/min), neoplasm, drug- or alcohol-
dependency, smoking, obstructive sleep apnea syndrome,
or visceral obesity.
The project was conducted with approval from the
Ethics Committee of Medical University of Warsaw. The
participants provided written informed consent prior to
participation.
MetS diagnosis was determined based on data in med-
ical records (anthropometric data, biochemical data, and
medical history). MetS was defined according to the
Third Report of the National Cholesterol Education Pro-
gram adult treatment panel III criteria of 2004, and re-
quired ≥ 3 of the 5 equally weighted criteria: (1) waist
circumference > 102 cm in men and > 88 cm in women,
(2) blood pressure > 130/85 mmHg, or diagnosed and
treated hypertension, (3) serum high density lipoprotein
cholesterol (HDL-C) < 40 mg/dL (1.03 mmol/L) in men
and <50 mg/dL (1.3 mmol/L) in women, (4) serum tri-
glycerides (TG) ≥ 150 mg/dL (1.7 mmol/L) or diag-
nosed and treated dyslipidemia, or (5) fasting serum
glucose ≥ 100 mg/dL (5.6 mmol/L) or diagnosed and
treated diabetes [11]. The same criterion for waist cir-
cumference (WC) for Caucasians was defined in the 2009
scientific consensus [12].
All participants underwent an anthropometric assess-
ment, which included measurements of WC, hip cir-
cumference, and weight. WC (cm) was measured as the
midpoint between the lowest rib and the iliac crest. The
waist-hip ratio (WHR), and body mass index (BMI) were
calculated. BMI, WHR, and WC are all established, sim-
ple clinical tests to assess excess body mass. BMI is the
most common indicator used in clinical practice and
epidemiological studies owing to its repeatability and its
confirmed correlation with WC [13,14]. Abnormal body
mass in the present study was defined as BMI ≥25 kg/m2
and obesity as BMI ≥30 kg/m2.
Biochemical measurements
Venous blood was collected in the morning, after fasting
for at least 8 hours. All blood analyses were performed
in the central laboratory of our hospital using Roche
Table 1 Clinical characteristics of the studied groups
(medians and IQR)
fhMetS (n = 78) Control group (n = 12) p
Age (years) 35.0 (31.0–39.0 ) 32.5 (27.0–37.0 ) 0.256
Body mass (kg) 75.5 (59.0–93.0) 69.5 (58.0–81.0) 0.267
WC (cm) 84.5 (70.0–97.5) 77.9 ( 67.0–88.1) 0.102
BMI (kg/m2) 25.3 (21.9–28.7 ) 23.6 (22.5–26.0) 0.499
WHR 0.9 (0.8–0.9) 0.8 (0.8–0.9) 0.365
Creatinine (mmol/L) 79.56 (53.04–106.08) 53.04 (61.88–97.24) 0.681
eGFR (ml/min) 84.4 (74.9–92.7) 82.3 (71.7–89.9) 0.420
Uric acid (umol/L) 261.71 (220.0–339.0) 261.72 (237.92–285.5) 0.879
AST (U/L) 19.0 (16.0–24.0) 17.1(13.0–22.0) 0.248
ALT (U/L) 22.0 (15.0–32.0) 13.5 (10.0–22.5) 0.118
ESR (mm) 7.0 (4.0–13.5) 8.0 (6.0–16.0) 0.462
WBC (G/L) 6.1 (5.1–7.2) 6.9 (5.2–9.7) 0.310
hsCRP (mg/L) 1.3 (0.8–2.5) 1.1 (0.4–5.8) 0.704
WC- waist circumference, BMI- body mass index, WHR- waist/hip ratio,
GFR- glomerular filtration rate, AST-aspartate transaminase, ALT- alanine
aminotransferase, ESR erytrocyte sedimentation rate, WBC- white blood cell
count, hsCRP- high-sensitivity C-reactive protein.
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analyzer Roche Cobas 6000 (c501 and e601). Fasting
plasma glucose was measured using the enzymatic col-
orimetric hexokinase method (coefficient of variation
[CV] less than 1.3%). Total plasma cholesterol (TC)
and TG were assayed using the enzymatic colorimetric
method with cholesterolesterase oxidase and glycerol
phosphate oxidase, respectively (CV less 1.6% for TC
and less than 2.0% for TG). HDL-C was assayed using
the enzymatic colorimetric method with polyethylene
glycol (CV less than 1.5%). Serum creatinine levels were
assayed using the Jaffe method ( CV less than 3.5%). As-
partate transaminase (AST) and alanine aminotransfer-
ase (ALT) were assayed using the International
Federation of Clinical Chemistry method (CV less than
3.1% for AST and 1.4% for ALT). Uric acid was assayed
using the enzymatic colorimetric method with uricase
(CV less than 1.6%). Glycated hemoglobin (HbA1c)
was measured using a turbidimetric inhibition immuno-
assay (CV less than 2.0%). High sensitivity C-reactive pro-
tein (hsCRP) was measured using an immunoturbidimetric
latex method (CV less than 1.3%). Low-density lipoprotein
cholesterol (LDL-C) was calculated using the Friedewald
formula (there were no subjects with TG > 400 mg/dL).
Non-HDL-C was calculated using the following formula:
TC– HDL-C = non-HDL-C. The insulin concentration
was measured using an electrochemical method (Roche,
ELECSYS 2010 syste), and the normal range is 2.5 – 24.9
μU/mL. Insulin resistance was assessed by homeostasis
model assessment-estimated insulin resistance (HOMA-
IR), which was calculated using the following formula: fast-
ing insulin (mU/L) × fasting glucose (mmol/L) / 22.5 [15].
Blood pressure measurements
Ambulatory blood pressure monitoring (24-hour ABPM)
was performed using the Spacelabs ABPM system every
20 minutes during the day (6 am–10 pm) and every
30 minutes at night (10 pm–6 am). The mean daytime
systolic blood pressure (D-SBP), mean daytime diastolic
blood pressure (D-DBP), mean nighttime systolic blood
pressure (N-SBP), and mean nighttime diastolic blood
pressure (N-DBP) were calculated. A resting electrocar-
diogram was performed using 12 standard leads and the
Spacelabs device, and a treadmill test was conducted
(Cambridge Hart CH 2000, Cardiac Diagnostic System
USA). Echocardiograms were performed using a Phillips
IE 33 system (Andeouver, Massachusetts, USA) with a
2.5 – 3.5 MHz transducer.
Nutritional habits and physical activity assessment
All subjects completed standardized questionnaires re-
garding nutritional and physical activity habits [16,17].
Questions for nutritional habits included the number of
meals per day, and their timing; frequency and amountof vegetables, fruits, sweets, and meat; and type and
quantity of fluids consumed. Physical activity was classi-
fied as low (sedentary life-style), if physical exercises last-
ing at least 30 minutes was performed, (not at all, once a
week, several times a month, or less frequently). The
moderate classification was defined as physical exercises
2–3 times per week. The high classification was defined
as ≥ 4 times per week.
Statistical analysis
Data are presented as median and interquartile range.
Statistical analysis was performed using the one-tailed
Mann–Whitney test for comparison of quantitative vari-
ables between 2 groups. Association between quantita-
tive variables were tested using Spearman correlation
coefficients. All analyses were conducted using SAS 9.3
(SAS Institute, Cary, NC, USA).
Results
No differences were found between the groups in nutri-
tional habits or level of physical activity. Approximately
20% of the subjects were moderately physically active,
and none of the subjects participated in a high level of
physical activity. There were no differences between the
groups in age, weight, WC, BMI, or WHR, nor were
there differences in the biochemical parameters (creatin-
ine, uric acid, AST, ALT, erythrocyte sedimentation rate,
white blood cell count, or hsCRP), which were within
the normal ranges in both groups (Table 1). However,
abnormal body mass, defined as BMI ≥ 25 kg/m2, was
present in 53.2% of the fhMetS participants and 41.6%
Table 2 Parameters of lipid and carbohydrate metabolism
in studied groups (medians and IQR)
fhMetS (n = 78) Control group (n = 12) P
TC (mmol/L) 5.46 (2.21–6.08) 4.69 (1.27–5.55) < 0.030
LDL-C (mmol/L) 3.28 (2.68–3.95) 2.90 (2.39–3.07) < 0.032
HDL-C (mmol/L) 1.46 (1.17–1.51) 1.51 (1.16–1.65) 0.976
nonHDL-C (mmol/L) 3.74 (3.30–4.63) 3.25 (2.64–3.70) < 0.016
TG (mmol/L) 1.03 (0.75–1.63) 0.77 (0.61–1.31) 0.339
Fasting glucose
(mmol/L)
4.51 (4.29–4.73) 4.81 (4.54–5.01) < 0.042
Fasting insulin
(μU/ml)
6.2 (4.3–8.3) 5.9 (5.1–8.2) 0.871
HOMA-IR 1.24 (0.82–1.83) 1.27 (1.01–1.94) 0.748
HbA1c (%) 5.5 (5.3–5.7) 5.5 (5.3–5.5) 0.268
TC- total cholesterol, LDL-C low- density lipoprotein cholesterol,
HDL-C- high- density lipoprotein cholesterol, TG- triglyceride, HbA1c-glycated
hemoglobin A1c.
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was noted in 19.4% of the fhMetS participants and none
of the control group. The fhMetS group had significantly
higher total cholesterol (p < 0.030), LDL-C (p < 0.032),
and non-HDL-C (p < 0.016) values than the control
group (Table 2), with 67.5% and 59.7% of the fhMetS
participants and 41.6% and 33.3% of the control partici-
pants with a TC concentration ≥ 4.94 mmol/L and a LDL-C
concentration ≥ 2.99 mmol/L respectively. In addition the
fhMetS group was characterized by a higher frequency
of participants with a TG concentration ≥ 1.71 mmol/L
than the control group (18.18% vs. 16.7%, p = 0.99),
and a lower frequency of participants with an HDL-C
concentration ≥ 1.30 mmol/L (62.3% vs. 66.6%, p = 0.99).
The TG concentration was significantly higher (p < 0.01)
and HDL-C levels were significantly lower (p < 0.001) in
the fhMetS participants with an abnormal body mass than
the fhMetS subjects with a normal body mass. The athero-
genic index (TG/HDL-C ratio) was significantly higher in
the overweight and obese fhMetS participants compared to
the fhMetS participants with normal body mass (p < 0.002)





TC 5.41 (4.77–6.02) 5.54 (4.81–5.98)
LDL-C 3.20 (2.61–3.67) 3.46 (2.76–4.16)
HDL-C 1.69 (1.44–2.03) 1.25 (1.14–1.46)
nonHDL-C 3.55 (2.98–4.16) 4.29 (3.38–4.63)
TG 0.82 (0.52–1.13) 1.21 (0.92–1.80)
TG/HDL ratio 1.18 (0.55–1.59) 2.23 (1.63–3.40)
Normal -BMI < 25 kg/m2, Overweight- BMI ≥ 25 kg/m2, Obese- BMI ≥ 30 kg/m2.fasting glucose values (4.51 mmol/L vs. 4.81 mmol/L,
p < 0.042) and higher fasting insulin values, although
this difference was not significant (Table 2). A signifi-
cant positive correlation between the fasting glucose
and fasting insulin concentrations was detected in the
fhMetS group (r = 0.28, p < 0.015) but not in the control
group. HbA1c levels were within the normal range in both
groups (p = 0.748). Significantly higher D-SBP, D-DBP and
N- DBP (p < 0.035, p < 0.045, and p < 0.019) were present
in the fhMetS group than in the control group (Table 4).
The frequency of the daytime SBP values > 140 mmHg
and DBP values >90 mmHg in the fhMetS group were
3.9% and 7.8% respectively, while the frequency of night-
time SBP values > 125 mmHg and DBP values >80 mmHg
were 5.1% and 1.3% respectively.
Discussion
Based on the comparison of young healthy adults who
were children of parents with confirmed MetS, and age-
and sex-matched healthy controls without a family
history of MetS in the present study, we detected differ-
ences in some of the MetS components. Furthermore,
more than half of the adults with a family history of
MetS had abnormal body mass, and 1 in 5 were obese.
Owing to the similarity in nutritional and physical activ-
ity habits between the groups, the high prevalence of ab-
normal body mass in the adults with a family history of
MetS may reflect a predisposition to increased body
weight in these individuals. A number of epidemiological
studies have shown a relationship between excess body
mass (overweight and obesity) and all-cause and cardio-
vascular mortality [18,19]. Moreover, adipose tissue, es-
pecially visceral adipose tissue, is related to abnormal
lipid metabolism and induces insulin resistance in tissues.
Atherogenic dyslipidemia is characterized by decreased
HDL cholesterol concentrations, hypertriglyceridemia, and
increased concentrations of small dense LDL particles. A
strong positive correlation was found between the risk of
cardiovascular disease and both TC and LDL concentra-
tions in healthy men and women as well as in patients with









5.07 (4.21–6.45) 0.798 0.681 0.749
3.25 (2.29–4.91) 0.199 0.614 0.813
1.12 (0.88–1.35) 0.0007 0.0001 0.041
3.90 (3.33–5.54) 0.094 0.154 0.922
1.64 (0.75–2.59) 0.0007 0.012 0.627
3.35 (1.27–6.53) 0.0001 0.002 0.294
Table 4 The characteristics of study groups according to
ABPM values (medians and IQR)
mmHg fhMetS (n = 78) Control group (n = 12) p
D-SBP 121.5 (112.5–129.5) 113.3 (107.5–121.5) <0.035
D-DBP 79.0 (74.0–83.5) 74.5 (68.5–78.0) <0.045
N-SBP 105.0 (97.0–113.0) 101.0 (93.5–106.0) 0.244
N-DBP 64.0 (60.0–70.0) 59.5 (53.5–65.0) <0.019
D-SBP- daytime systolic blood pressure, D-DBP- daytime diastolic blood
pressure, N-SBP- nighttime systolic blood pressure, N-DBP- nighttime diastolic
blood pressure.
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of MetS had elevated TC (≥4.94 mmol/L) and LDL-C
(≥2.99 mmol/L) levels in addition to a greater frequency of
high TG concentrations and lower HDL-C values. As with
BMI, this is likely related to a family predisposition for ab-
normal lipid profiles, rather than differences in nutritional
and physical activity habits. The 2012 European Guidelines
for the prevention of cardiovascular diseases recom-
mend the use of non-HDL-C as a parameter to quantify
the amount of atherogenic lipoproteins containing apoli-
poprotein B, which allows the prediction of CVD risk to
a similar extent or even more accurately than LDL-C
[5,21]. The present study reported a significantly higher
mean non-HDL cholesterol concentration in the group
with a family history of MetS than in the control group
(p < 0.016). Regarding insulin levels, previous studies
have demonstrated that, relationships exist between adi-
pose tissue, insulin, the progression of insulin resistance,
and hyperinsulinemia, although these relationships have
not yet been well defined. A significant relationship has
been demonstrated between insulin concentration and
the risk of cardiovascular death, independent of other
established risk factors, in people without diabetes [22].
Although the fasting glucose and insulin values were nor-
mal in both groups in the present study, a significant
positive correlation was found between glucose and insu-
lin concentrations in the group with fhMetS (r= 0.28,
p < 0.015). This finding may indicate greater insulin re-
sistance in tissues. However, HOMA-IR did not exceed
2.5 in any of the participants, and there was no differ-
ences in HOMA-IR between the groups. Experimental
and clinical studies have also shown a relationship be-
tween adipose tissue and progression to and maintenance
of elevated blood pressure [23]. The National Health and
Nutrition Examination Survey III study results demon-
strated that the prevalence of arterial hypertension in-
creases with increasing BMI [24]. A positive correlation
has also been found between BMI, lipid disorders, arterial
hypertension, and the progression of atherosclerotic pla-
ques in young people. In our study the ABPM resulted in
significantly higher mean values of SBP and DBP in the
daytime and DBP at nighttime in the participants with afamily history of MetS, although less than 8% of these
participants had elevated blood pressure. Population stud-
ies indicate that a family history of MetS is a marker of a
strong genetic predisposition for cardiometabolic compli-
cations [25,26]. The results of the WHO–MONICA study,
conducted in the French population, suggest that MetS
should be assessed as an independent risk factor for the
early onset of cardiovascular disease [25]. In the National
Heart, Lung, and Blood Institute Family Heart Study, a
family history of diabetes, and arterial hypertension re-
sulted in a predisposition for carbohydrate and lipid meta-
bolic disorders, which was especially true for non-obese
individuals [26]. Such disorders appeared at a young age
[27]. Similar results were demonstrated in the present
study, in which there was a tendency for the early develop-
ment of metabolic disorders in young persons with
fhMetS. Collectively, the results of the present study indi-
cate that abnormal body mass and lipid disorders, includ-
ing those of total cholesterol and LDL cholesterol, are the
most frequent metabolic disorders in young persons with
a family history of MetS. This study has certain limita-
tions, including a small sample size resulting from very
rigorous inclusion and exclusion criteria intended to ob-
tain homogenous groups. The parental history of MetS
was confirmed in the fhMetS group and excluded in the
control group.
However to the best of our knowledge, this is the first
study documenting the typical metabolic alterations in
MetS in healthy young adult children of parents with
confirmed MetS. The results suggest that early screening
for risk factors of MetS, such as overweight and hyper-
cholesterolemia, should be conducted in this group.
However, additional studies are required to confirm our
findings.Conclusions
Owing to the high frequency of overweight/obesity and
lipid disorders, which are considered MetS risk factors
for cardiovascular disease, in the healthy young adults
with a family history of MetS, this group should be con-
sidered at high risk and undergo regular screening.
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